<DOC>
	<DOC>NCT01561352</DOC>
	<brief_summary>This trial is conducted in the United States of America (USA). The aim of this trial is to assess the efficacy of activated recombinant human factor VII in the treatment of refractory haemorrhagic cystitis (HC) following chemotherapy.</brief_summary>
	<brief_title>Efficacy and Safety of Activated Recombinant Human Factor VII in Refractory Haemorrhagic Cystitis</brief_title>
	<detailed_description />
	<mesh_term>Cystitis</mesh_term>
	<criteria>Severe haemorrhagic cystitis (HC) Patients with overt DIC (disseminated intravascular coagulation) Patients with known active atherosclerotic disease, such as active coronary artery disease or recent stroke in the past 3 months Central venous access device related thrombus in the last 3 months Patients with allergy to activated recombinant human factor VII or any component of its preparation</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>